Found: 32
Select item for more details and to access through your institution.
Editorial: clinical impact of sofosbuvir renal toxicity—more light on the way.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1052, doi. 10.1111/apt.16861
- By:
- Publication type:
- Article
Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination—authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1061, doi. 10.1111/apt.16862
- By:
- Publication type:
- Article
Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B? Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1044, doi. 10.1111/apt.16886
- By:
- Publication type:
- Article
Editorial: reply to delayed gastric emptying as an independent predictor of mortality in gastroparesis—it is clinically relevant after all! Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1048, doi. 10.1111/apt.16885
- By:
- Publication type:
- Article
Letter: potential selection bias in real‐world comparison of ustekinumab versus vedolizumab as a second‐line treatment for Crohn's disease—authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1070, doi. 10.1111/apt.16896
- By:
- Publication type:
- Article
Editorial: is there a role for monitoring intermediate anti‐TNF drug concentrations in IBD?
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1049, doi. 10.1111/apt.16889
- By:
- Publication type:
- Article
Editorial: is there a role for monitoring intermediate anti‐TNF drug concentrations in IBD? Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1051, doi. 10.1111/apt.16893
- By:
- Publication type:
- Article
Letter: the value of quality liver biopsy before initiation of corticosteroids for severe alcoholic hepatitis‐authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1072, doi. 10.1111/apt.16890
- By:
- Publication type:
- Article
Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn's disease? Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1040, doi. 10.1111/apt.16866
- By:
- Publication type:
- Article
Letter: sPD‐1 as a predictor for HBsAg seroclearance—shed light on inactive carriers with chronic hepatitis B. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1057, doi. 10.1111/apt.16863
- By:
- Publication type:
- Article
Letter: inflammatory bowel disease services during the Covid‐19 pandemic ‐ authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1064, doi. 10.1111/apt.16884
- By:
- Publication type:
- Article
Meta‐analysis: hepatitis B vaccination in inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 908, doi. 10.1111/apt.16880
- By:
- Publication type:
- Article
Editorial: delayed gastric emptying as an independent predictor of mortality in gastroparesis—it is clinically relevant after all!
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1046, doi. 10.1111/apt.16857
- By:
- Publication type:
- Article
Meta‐analysis: prevalence of, and risk factors for, non‐alcoholic fatty liver disease in patients with inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 894, doi. 10.1111/apt.16879
- By:
- Publication type:
- Article
Letter: skipping breakfast is associated with an increased long‐term cardiovascular mortality in metabolic dysfunction‐associated fatty liver disease (MAFLD) but not in MAFLD‐free individuals. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1067, doi. 10.1111/apt.16876
- By:
- Publication type:
- Article
Editorial: some of the obstacles in managing mood disorders in IBD.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1054, doi. 10.1111/apt.16875
- By:
- Publication type:
- Article
Letter: potential selection bias in the real‐world comparison of ustekinumab versus vedolizumab as a second‐line treatment for Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1069, doi. 10.1111/apt.16871
- By:
- Publication type:
- Article
Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B?
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1042, doi. 10.1111/apt.16854
- Publication type:
- Article
Letter: inflammatory bowel disease services during the Covid‐19 pandemic.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1063, doi. 10.1111/apt.16841
- By:
- Publication type:
- Article
Review article: Lynch Syndrome—a mechanistic and clinical management update.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 960, doi. 10.1111/apt.16826
- By:
- Publication type:
- Article
Prevalence of HFE‐related haemochromatosis and secondary causes of hyperferritinaemia and their association with iron overload in 1059 French patients treated by venesection.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1016, doi. 10.1111/apt.16775
- By:
- Publication type:
- Article
Letter: skipping breakfast is associated with an increased long‐term cardiovascular mortality in metabolic dysfunction‐associated fatty liver disease (MAFLD) but not MAFLD‐free individuals.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1065, doi. 10.1111/apt.16849
- By:
- Publication type:
- Article
Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 978, doi. 10.1111/apt.16807
- By:
- Publication type:
- Article
Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn's disease?
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1038, doi. 10.1111/apt.16843
- By:
- Publication type:
- Article
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 921, doi. 10.1111/apt.16788
- By:
- Publication type:
- Article
A novel phenotype‐based drug‐induced liver injury causality assessment tool (DILI‐CAT) allows for signal confirmation in early drug development.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1028, doi. 10.1111/apt.16836
- By:
- Publication type:
- Article
Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1059, doi. 10.1111/apt.16834
- By:
- Publication type:
- Article
Letter: sPD‐1 as a predictor for HBsAg seroconversion—shed light on inactive carriers with chronic hepatsitis B.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1056, doi. 10.1111/apt.16833
- By:
- Publication type:
- Article
Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 944, doi. 10.1111/apt.16794
- By:
- Publication type:
- Article
NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 1008, doi. 10.1111/apt.16769
- By:
- Publication type:
- Article
A sequential approach using the age‐adjusted fibrosis‐4 index and vibration‐controlled transient elastography to detect advanced fibrosis in Korean patients with non‐alcoholic fatty liver disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 994, doi. 10.1111/apt.16766
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 8, p. 891, doi. 10.1111/apt.16418
- Publication type:
- Article